EX-10.2.1



 Exhibit 10.2.1 

CONFIDENTIAL TREATMENT REQUESTED BY CELLECTIS S.A.—CONFIDENTIAL PORTIONS OF THIS DOCUMENT HAVE BEEN REDACTED AND HAVE BEEN SEPARATELY FILED WITH THE
COMMISSION. 
 AMENDMENT NO. 1 TO THE PATENT LICENSE AGREEMENT NO. C-00061906 

BETWEEN: 
 L’Institut Pasteur, 

Foundation recognized as having public utility, 
 25-28, rue du
Docteur Roux, 
 75724 Paris cedex 15, 
 represented by
Mr. Christian POLICARD, 
 Director of Development and Industrial Partnerships. 

Hereafter referred as to as “IP” or the “LICENSOR”, 

Party of the first part 
 AND: 

CELLECTIS 
 Public limited company with capital with a
capital of 122,363.47 euros, 
 with its registered office at at 28, rue du Docteur Roux, 75724 Paris cedex 15, 

represented by Mr. André Choulika, acting in the capacity of CEO 

Hereafter referred to as “CELLECTIS” or the “LICENSEE”, 

Party of the second part. 
 The LICENSOR and the LICENSEE
are hereafter referred to as the “Parties”. 
 RECITALS: 

IP owns patents and patent applications relating to a method of homologous recombination. 

On June 19, 2000, the Parties signed licensing agreement no. C-00061906 (hereafter the “AGREEMENT”), by which the LICENSOR grants the LICENSEE
exploitation rights under the above mentioned patents and patent applications. 
 After discussions and exchanges between the Parties, they have decided to
modify the provisions of the AGREEMENT. 
 It is thus agreed as follows: 

ARTICLE 1 
 1.1 The Parties agree that the words
defined in Article 1, “DEFINITIONS”, of the AGREEMENT, as they are used in this amendment, have the same definitions as in the AGREEMENT and form an integral part of this amendment. 







 1.2 The following definitions apply for the purposes of this amendment, it being understood when permitted by
context that the singular shall be considered to include the plural and vice versa 
  

	 	1.2.1	By “I-SceI and/or I-Spom I” the Parties agree to mean the technologies claimed by the AGREEMENT PATENTS of LICENSE AGREEMENT no. C-00061901 signed between the Parties. 


 

	 	1.2.2	By “PGN”, the Parties agree to mean the technologies claimed by the AGREEMENT PATENTS of LICENSE AGREEMENT no. C-00061906 signed between the Parties. 


 

	 	1.2.3	By “Mulligan”, the Parties agree to mean the technologies claimed by the AGREEMENT PATENTS of LICENSE AGREEMENT no. C-00061905 signed between the Parties. 


 

	 	1.2.4	For the sole purposes of articles 3.4 and 3.5 as modified by this amendment, the word “TOOL” will have the definition stated below: 


By “TOOL”, the Parties agree to mean the use by the LICENSEE’S SUB-LICENSEE of the LICENSED PROCESSES or LICENSED PRODUCTS for
internal purposes or as part of the research or development process conducted by the sub-licensee. 
 ARTICLE 2 

Article 2.4 of the AGREEMENT is modified by the following provisions, which supersede all previous provisions of that same article: 

 

	“2.4	The LICENSEE may only grant sub-licenses to THIRD PARTIES for the rights which it receives under this Agreement with the prior AGREEMENT of the LICENSOR. If the LICENSOR does not communicate its disagreement within
twenty-one days from the notification of a sub-licensing project, it shall be considered to have agreed. 

 The LICENSOR may
refuse to grant prior agreement for a sub-license only for serious cause. 
 The following would constitute serious cause justifying
IP’s refusal to agree: a sub-licensing Amendment between the LICENSEE and a THIRD PARTY containing provisions which are contrary to the ethics, image or intellectual property of the LICENSOR.” 

ARTICLE 3 
 Article 3.4 of the AGREEMENT is
modified by the following provisions, which supersede all previous provisions of the same article: 
  

	“3.4.1	For sub-licenses concerning a LICENSED PATENT for the use of TOOLS granted by the LICENSEE under Article 2.4 of this AGREEMENT, the LICENSEE will pay the LICENSOR [***] of any compensation it receives, lump sums,
royalties, market values (for cross-licensing or exchanges) for all sub-licenses granted to THIRD PARTIES.” 

  

	3.4.2	For sub-licenses concerning LICENSED PATENTS other than those mentioned in Article 3.4.1 above, granted by the LICENSEE under Article 2.4 of this AGREEMENT, the LICENSEE will pay to the LICENSOR [***] of any
compensation it receives, lump sums, royalties, market 

  
 [***]
CONFIDENTIAL MATERIAL REDACTED AND SEPARATELY FILED WITH THE COMMISSION. 








	 	
values (for cross-licensing or exchanges) for all sub-licenses granted to THIRD PARTIES, excluding the amounts stipulated in Article 3.5, without the amount of the royalties owed to the LICENSOR
being less than: 

  

	 	•	 	[***] of the net income of the sub-licensee for the ISCEI and/or I-Spom I technologies, Mulligan and PGN granted together to the same sub-licensee; 


 

	 	•	 	[***] of the net income of the sub-licensee for ISCEI and/or I-Spom I technologies granted alone or with Mulligan to the same sub-licensee. 


ARTICLE 4 
 The last sentence of article 10.1 par.
2 is modified as follows: 
 “This share must not be less than [***] per year.” 

ARTICLE 5 
 Article 2.6 of the licensing AGREEMENT
is modified by the following provisions, which supersede all previous provisions of the same article: 
 “The IMPROVEMENTS achieved by the LICENSOR are
exclusively licensed to the LICENSEE for a period of 5 (five) years following the date of signature of Amendment no. 1 to this AGREEMENT. 
 “The
LICENSOR will inform the LICENSEE of the existence and contents of the IMPROVEMENTS. 
 “Following the 5 year period, the Parties will come together to
mutually agree on the terms of access to the IMPROVEMENTS.” 
 ARTICLE 6 

The last sentence of article 1.5 of the AGREEMENT is modified as follows: 

“Patents filed to protect IMPROVEMENTS will be included in the AGREEMENTS PATENTS under the AGREEMENT in accordance with the provisions of Article 2.6 of
this AGREEMENT.” 
 ARTICLE 7 
 This
amendment will enter into force on the date of its signature. 
 The other provisions of the AGREEMENT remain unchanged and in force between the Parties.

  

			
	Signed in Paris on		[Handwritten text: September 8, 2003]
		
	in 2 original copies.		

  

			
	CELLECTIS		INSTITUT PASTEUR

  
 [***] CONFIDENTIAL MATERIAL REDACTED AND SEPARATELY
FILED WITH THE COMMISSION.